Recent Updates
Recently added Catalysts
BHST Positive Sentiment Score: 70/100

BIOHARVEST SCIENCES INC.

Tuesday, September 9, 2025 3 min read
Key Takeaway: BioHarvest Sciences Inc. has announced the effectiveness of its shelf registration statement on Form F-3 with the SEC. This allows the company to offer and sell up to $100 million in common shares, warrants, and units as needed depending on market conditions and capital requirements. Importantly, the registration does not obligate the company to sell any specific amount, maintaining flexibility. The move is intended to enhance the company's liquidity and support future initiatives, although it introduces variability based on market dynamics.

Market Sentiment Analysis

POSITIVE FACTORS

  • Effectiveness of the shelf registration statement may enhance liquidity.
  • Company can raise up to $100 million for future projects.
  • The opportunity to expand operations without immediate obligation.

CONCERNS & RISKS

  • The offering depends on market conditions, adding uncertainty.
  • No commitment for specific amounts or timelines in securities sales.

Full Press Release Details

BIOHARVEST SCIENCES INC. ANNOUNCES EFFECTIVENESS OF SHELF REGISTRATION STATEMENT ON FORM F-3
Rehovot, Israel - September 8, 2025 - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE:8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the filing and effectiveness of a shelf registration statement (the Shelf Registration) on Form F-3 with the Securities and Exchange Commission ("SEC").
The Shelf Registration will allow the Company to offer and sell, from time to time, up to an aggregate of USD $100 million of its common shares, warrants and units, or a combination thereof (together, the "Securities"), on a registered basis, subject to market conditions, the Company's capital needs, and limitations imposed by SEC rules and applicable securities laws. The terms of any offering, including the price of Securities, will be determined at the time of such offering and be described in a prospectus supplement that will be filed with the SEC.
The Shelf Registration does not constitute a commitment by the Company to sell any specific amount of Securities. Any further offering under the Shelf Registration, if made, will be subject to the Company's discretion and applicable market conditions.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the Securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under applicable securities laws.
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations

Frequently Asked Questions

What is the purpose of BioHarvest's shelf registration statement?

The statement allows BioHarvest to offer up to $100 million in securities, including shares and warrants, subject to market conditions.

What does the shelf registration allow BioHarvest to sell?

It permits the sale of common shares, warrants, and units for a total of $100 million.

Is BioHarvest obligated to sell specific amounts of securities?

No, the shelf registration does not commit BioHarvest to sell any specific amounts of securities.

What does the company mean by forward-looking statements?

These statements reflect management's estimates and expectations but are subject to risks and uncertainties.

What sectors is BioHarvest focusing on with its technology?

BioHarvest targets contract development and production and proprietary nutraceutical health products.

Tags: BHST Viatris Investor Conferences Healthcare BioHarvest Sciences shelf registration SEF liquidity
Last updated: Sep 9, 2025